NEW YORK (GenomeWeb News) – Foundation Medicine's today said that its genomic tests will be used by biopharmaceutical company Celgene for clinical trials of its anti-cancer drug candidates.
Foundation's test, which is under development, will be used to hasten faster recruitment of target patient populations and for broad genetic characterization of trial enrollees in order to identify patients most likely to respond to Celgene's drug candidates.
Foundation's test will use next-generation sequencing for the analysis of routine clinical samples, such as paraffin-embedded tumors, to identify molecular changes in more than 200 cancer-related genes. The test will be optimized for clinical-grade analysis of tumor tissues so that multiple complexities inherent in tumor genomes can be overcome, the Cambridge, Mass.-based firm said.
Financial and other terms of the deal were not disclosed.
Foundation also is developing the test for use by pathologists and oncologists and said it expects to receive CLIA certification. Results of the test will be reported through a secure, interactive website on which genomic data and a structured knowledgebase of relevant, publicly available scientific and medical information are linked.
Foundation said that it also intends to post information on relevant clinical trials on its website.
In January, Foundation inked its first deal with a pharmaceutical firm, Novartis. Under that deal, Novartis is using Foundation Medicine's cancer genome panel test for its clinical trials.